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clinical trial, 11 in which   -glutamyl-
transpeptidase and alkaline phosphatase 
served as biomarkers. Patients were enrolled 
on the basis of the diagnostic elevation of 
the calculated product of these biomarkers, 
which were normalized to urinary creati-
nine. Th e fi rst dose of erythropoietin (EPO) 
was given within about 6 hours of the 
biomarker-confi rmed insult, and the sec-
ond dose at 30 hours. Controls with iden-
tical biomarker profi les were treated with 
vehicle. Th e rationale for the use of EPO 
included its demonstrated antiapoptotic, 
anti-infl ammatory, and mitogenic actions 
in EPO receptor-expressing animal and 
renal cells. 13 Disappointingly, EPO failed 
to improve outcomes versus control sub-
jects, indicating that either the biomarkers 
used or the tested treatment protocol may 
have been suboptimal. Th is is again in 
contrast to preclinical studies with EPO, 
all of which showed good renoprotective 
activity in otherwise healthy animals. 
 In conclusion, the current status of opti-
mal biomarker and AKI therapy develop-
ments, as also illustrated by Rouse  et al. , 6 
does identify a number of important 
points: (1) Novel AKI biomarkers, parti-
cularly when used in combination panels, 
possess greater specifi city and earlier diag-
nostic and prognostic sensitivity than 
serum creatinine and blood urea nitrogen, 
during both the injury and the recovery 
phases of AKI. (2) Changes in urinary 
profi les of these very diverse biomarkers 
do largely occur in a temporally parallel 
pattern during the injury (higher specifi -
city) and recovery (lower specificity) 
phases of nephrotoxin-induced AKI. (3) 
Changes in urinary biomarkers illustrate 
distinct renal responses to injury, such 
as shedding of proximal tubular brush bor-
der components and cytosolic proteins /
 enzymes, while also identifying their 
individual roles in defensive and repair-
supporting mechanisms that may serve as 
the basis for the future development of 
novel therapeutic approaches. (4) Initial 
proof of principle for both biomarkers 
(specifi city, sensitivity) and interventions 
(effi  cacy) is most optimally tested in suit-
able clinical AKI models, such as open 
heart surgery patients and kidney trans-
plant recipients. (5) Effi  cacy of novel ther-
apies should be established in relevant 
preclinical animal models. (6) Eff ective 
therapies should optimally target all major 
components of renal injury and recovery. 
(7) It is hoped that select biomarkers may 
aid the physician in pinpointing the time 
when specifi c therapies are most eff ective. 
 DISCLOSURE 
 During the preparation of this Commentary, 
the author served as a consultant to AlloCure. 
 REFERENCES 
 1 .  Vaidya  VS ,  Ferguson  MA ,  Bonventre  JV .  Biomarkers 
of acute kidney injury .  Annu Rev Pharmacol Toxicol 
 2008 ;  48 :  463 – 493 . 
 2 .  Cruz  DN ,  Ricci  Z ,  Ronco  C .  Clinical review: RIFLE 
and AKIN — time for reappraisal .  Crit Care  2009 ;  13 : 
 211 ;  doi:10.1186/cc7759 . 
 3 .  Waikar  SS ,  Sabbisetti  VS ,  Bonventre  JV . 
 Normalization of urinary biomarkers to creatinine 
during changes in glomerular filtration rate . 
 Kidney Int  2010 ;  78 :  486 – 494 . 
 4 .  Mori  K ,  Lee  HT ,  Rapoport  D  et al.  Endocytic delivery 
of lipocalin-siderophore-iron complex rescues 
the kidney from ischemia-reperfusion injury . 
 J Clin Invest  2005 ;  115 :  610 – 621 . 
 5 .  Ichimura  T ,  Asseldonk  EJ ,  Humphreys  BD  et al. 
 Kidney injury molecule-1 is a phosphatidylserine 
receptor that confers a phagocytic phenotype on 
epithelial cells .  J Clin Invest  2008 ;  118 :  1657 – 1668 . 
 6 .  Rouse  RL ,  Zhang  J ,  Stewart  SR  et al.  Comparative 
profile of commercially available urinary 
biomarkers in preclinical drug-induced kidney 
injury and recovery in rats .  Kidney Int  2011 ;  79 : 
 1186 – 1197 . 
 7 .  Togel  F ,  Isaac  J ,  Hu  Z  et al.  Renal SDF-1 signals 
mobilization and homing of CXCR4-positive cells 
to the kidney after ischemic injury .  Kidney Int  2005 ; 
 67 :  1772 – 1784 . 
 8 .  Hsu  CY ,  Ordonez  JD ,  Chertow  GM  et al.  The risk of 
acute renal failure in patients with chronic kidney 
disease .  Kidney Int  2008 ;  74 :  101 – 107 . 
 9 .  Allgren  RL ,  Marbury  TC ,  Rahman  SN  et al.  Anaritide 
in acute tubular necrosis. Auriculin Anaritide Acute 
Renal Failure Study Group .  N Engl J Med  1997 ;  336 : 
 828 – 834 . 
 10 .  Hirschberg  R ,  Kopple  J ,  Lipsett  P  et al.  
 Multicenter clinical trial of recombinant 
human insulin-like growth factor I in patients 
with acute renal failure .  Kidney Int  1999 ;  55 : 
 2423 – 2432 . 
 11 .  Endre  ZH ,  Walker  RJ ,  Pickering  JW  et al.  Early 
intervention with erythropoietin does not 
affect the outcome of acute kidney injury 
(the EARLYARF trial) .  Kidney Int  2010 ;  77 : 
 1020 – 1030 . 
 12 .  Togel  FE ,  Westenfelder  C .  Mesenchymal stem cells: 
a new therapeutic tool for AKI .  Nat Rev Nephrol 
 2010 ;  6 :  179 – 183 . 
 13 .  Westenfelder  C .  Unexpected renal actions of 
erythropoietin .  Exp Nephrol  2002 ;  10 :  294 – 298 . 
 1 Miltenyi Biotec GmbH ,  Bergisch Gladbach , 
 Germany 
 Correspondence: Kai Pinkernell, Miltenyi 
Biotec GmbH, Friedrich Ebert Strasse 68, 51429 
Bergisch Gladbach, Germany. 
E-mail:  pinkerk@hotmail.com 
see original article on page 1198
cell transplantation. Th e results suggest 
a therapeutic benefit of this approach, 
independent of diff erentiation of the graft  
into a renal cell type, but dependent 
on the level of bone marrow chimerism. 
Chimerism levels correlate with improved 
functional parameters as well as histo-
pathological findings resulting in a 
therapeutic benefi t that cannot easily be 
explained by target tissue diff erentiation 
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 Yeagy and colleagues present long-term data from a preclinical 
model of cystinosis after hematopoietic stem cell transplantation. 
The results suggest a therapeutic benefit independent of target tissue 
differentiation but dependent on the level of bone marrow chimerism. 
The mode of action remains mysterious, but positive effects are seen. 
Although the work presents a potential therapeutic option for an 
otherwise dismal disease, the search for the mechanism of action in 
cellular therapies continues. 
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 Yeagy and colleagues 1 present long term 
follow-up data in a preclinical model of 
cystinosis aft er wild-type or green fl uores-
cent protein-labeled hematopoetic stem 
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and takeover of function. Th e mechanism 
of action remains mysterious like in many 
other areas of cellular therapy, but positive 
eff ects can be detected. Th e work on the 
one hand continues to stimulate the hunt 
for the mechanism of action in cellular 
therapies but on the other hand presents 
a very real potential therapeutic option for 
an otherwise dismal disease. 
 Th e therapeutic potential of hemato-
poietic stem cell transplantation in this 
preclinical model of cystinosis was shown 
by this group in an earlier publication. 2 
Interestingly, cells of the transplanted 
graft  could be detected in many organs 
displaying an interstitial phenotype 
rather than organ-typical cell types. 
Furthermore, the prior work suggested 
that this level of therapeutic benefi t could 
not be achieved solely with the use of 
mesenchymal stem cells, but that, rather, 
the full hemato poietic system needed 
replacement, resulting in a positive out-
come. Th is could suggest (1) that the mes-
enchymal stem cells used were insuffi  cient 
in number or not functional (the use of 
cells in passage 20 or other conditions 
could play a part in this), (2) that another 
cell type in the hematopoietic system car-
ries the regenerative / therapeutic proper-
ties, or (3) that the interplay of several cell 
types is necessary for a positive outcome 
(the appearance of several green fl uores-
cent protein-positive cell types in the kid-
ney could suggest this). 
 Seeing these results in the light of the 
current work by the group, 1 a long-term 
benefi t with the use of cellular therapy 
seems feasible, even in this type of hered-
itary defect, in which one would normally 
expect the need for a genetic correction in 
almost all cells of the body rather than 
only the hematopoietic system. Further-
more, hematopoietic stem cell transplan-
tation does seem to permanently cure or 
substantially improve the functional 
defect in the  Ctns   −  /  −   group even without 
any evidence of target tissue  diff erentiation 
and replacement of damaged cells as 
described in other disease models. 3 Th e 
biggest question, then, is: How does this 
work? Is cystinosin somehow transferred 
from the interstitial cell types, identifi ed 
as being from the graft , to surrounding 
cells (for example, the tubular epithelium 
in the kidney), leading to a rescue in 
 Figure 1  |  Putative mechanisms of action in cellular therapies. Several mechanisms have been 
postulated, ranging mainly from target tissue differentiation to paracrine pathways. A critical piece 
is still missing that would allow an explanation of all phenomena observed. The observed events 
are dependent on multiple variables, including the cell type transplanted and the underlying injury 
(e.g., acute ischemic vs chronic metabolic). 
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 function? Th e fact that a high percentage 
of chimerism correlates with a good func-
tional outcome would suggest that a 
certain level of functional wild-type cells 
in the target organs is necessary, similar to 
a dose dependency or a threshold dose. 
Diff usion of cystine and metabo lism in 
the donor cells or transport of cystinosin 
could ultimately be responsible for pro-
gressive clearance that is measurable in all 
organs. Th rough simple diff usion gradi-
ents, the donor cells might clear the oth-
erwise accumulating cystine if diff usion 
can be postulated, or if the functional pro-
tein somehow makes its way into the defi -
cient cells. 
 Even in older animals, transplantation 
led to a reduction in chronic kidney dis-
ease, which underlines the gradual 
increase in damage the genetic defect 
causes, suggesting a therapeutic window 
before irreversible changes occur that 
would prevent any benefit. It is also 
important to put this kind of chronic 
injury, with a gradual decrease in func-
tion, into perspective with acute disease 
models that were also studied. Acute 
kidney injury has been tested by several 
groups using various cellular therapy 
approaches, and despite the lack of 
evidence for permanent engraft ment, a 
therapeutic benefi t can be shown. 4 
 So where will we go from here? The 
results presented by Yeagy  et al. , 1 in the 
context of other work in the fi eld, suggest 
that we are still missing something — the 
critical piece of the puzzle that would 
result in the completion of a model to 
explain the diverse phenomena we see. 
For cellular therapies ( Figure 1 ): It is not 
diff erentiation into tubular epithelium or 
hepatocytes or cardiomyocytes; we rather 
see an improvement in function through 
an interstitial cell type, well in line with 
prior observations in acute models. 5 For 
cystinosis: It is not the correction of the 
defective gene in all cells of the body that 
results in a critical rescue of lysosomal 
function. Th e interstitial cell type seems 
capable of taking over the missing meta-
bolic function. 
 Still, much work must be done to fi gure 
out exactly how to apply this in the patient 
setting of cystinosis. A syngeneic donor 
pool, such as the one available in the 
mouse system, is something far away from 
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reality in the clinic. Taking allogeneic, 
hematopoietic donor cells will result in 
therapy-related mortality and morbidity 
that might push the risk – benefit ratio 
in the wrong direction. And last but 
not least, gene therapy approaches have 
their own set of issues — for example, 
vector safety, which becomes especially 
apparent when stem cells have to be 
transduced. 
 Th is is what most of us will love about 
the science part: seeing how the puzzle 
will be solved. In the meantime, we should 
think hard about how to help our patients. 
Ensuring safety and guided by an acceptable 
risk – benefit ratio, cellular therapies will 
have to be developed at the bench and the 
bedside, and the paper by Yeagy  et al. 1 is a 
great example of a very involved experimen-
tal system adding pieces to the puzzle to 
make a diff erence. 
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 Hexokinases (HKs) catalyze the fi rst com-
mitted step of glucose (Glc) metabolism, 
namely, the phosphorylation of Glc to 
yield glucose-6-phosphate. Th is reaction 
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maintains the concentration gradient per-
mitting facilitated Glc entry into cells and 
also initiates all major pathways of Glc 
utilization. 1 As such, this rate-controlling 
step is ideally positioned to infl uence the 
magnitude and direction of Glc flux 
within cells. Th e major HKI and HKII iso-
forms also exhibit a novel capacity for 
specific physical and functional inter-
action with mitochondria that directly 
couples and coordinates oxidative 
 phosphorylation with cytosolic Glc fl ux. 1,2 
Mitochondrial HKs have recently emerged 
as major mediators of the antiapoptotic 
eff ects of growth factors. 1,3,4 Competition 
with apoptogenic Bax and Bak for com-
mon mitochondrial binding sites and 
direct metabolic coupling with oxidative 
phosphorylation have both been impli-
cated in these effects. When examined 
in cells with intact mitochondria, partial 
or complete Glc dependence has been 
observed, suggesting specifi c metabolic 
requirements. 1 Gall  et al. 5 (this issue) now 
report the ability of mitochondrial HK to 
mitigate Bax-induced apoptosis in an 
adenosine triphosphate (ATP) depletion 
model of proximal tubule cell injury, sug-
gesting that metabolism  per se is not an 
absolute prerequisite for Bax antagonism. 
 Under normal conditions, proximal 
tubules exhibit a lower relative glycolytic 
capacity than other nephron segments 
and a heavy reliance on non-Glc energy 
substrates. 6 Although it does not follow 
that proximal tubule cells do not — or 
cannot — utilize Glc, these observations 
have led to the common misperception 
that Glc metabolism is unimportant in 
this nephron segment. Th ere is, however, 
con siderable evidence to the contrary. All 
mammalian cells can utilize Glc, 2 includ-
ing proximal tubule cells. 6 – 9 Although less 
than that observed in distal nephron seg-
ments, the total Glc-phosphorylating 
capacity of freshly isolated proximal 
tubules 10,11 is not much lower than that 
reported for normal muscle or adipose —
 tissues largely responsible for systemic Glc 
disposal. Th is suggests a substantial cellu-
lar capacity for Glc utilization, with the 
caveat that only a fraction of this capa-
city is probably required to support the 
demands of even the most Glc-avid cell 
types. 2 Th e corresponding ability to oxi-
dize Glc 11 is similarly comparable to that 
observed in adipocytes. As the only energy 
substrate that can be eff ectively utilized in 
the absence of O 2 , Glc has particular rele-
vance to ischemic or hypoxic conditions, 1 
so it is of considerable interest that proxi-
mal tubule glycolytic activity increases 
 in vivo following brief ischemia. 7 Similar 
changes can prevent ATP depletion, cellu-
lar injury, and transport dysfunction in 
proximal tubule preparations subjected 
to brief hypoxia or chemical anoxia. 12 
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 Hexokinases have emerged as novel mediators of the antiapoptotic 
effects of growth factors in a wide variety of cells. These effects have been 
attributed to highly regulated direct physical and functional interactions 
with mitochondria. The demonstration that mitochondrial hexokinases 
can prevent apoptogenic  ‘ Bax attack ’ in proximal tubule cells suggests a 
need to reexamine the specific contributions of hexokinases and glucose 
metabolism in this nephron segment and elsewhere within the kidney. 
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